Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.

Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F.

Cancer Res. 2005 Nov 1;65(21):10041-9.

2.

Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.

Susumu S, Nagata Y, Ito S, Matsuo M, Valmori D, Yui K, Udono H, Kanematsu T.

Cancer Sci. 2008 Jan;99(1):107-12. Epub 2007 Nov 7.

3.

Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.

Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, Maraskovsky E, Cebon J.

Blood. 2010 Jul 15;116(2):218-25. doi: 10.1182/blood-2009-10-249458. Epub 2010 Apr 29.

4.

Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.

Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M.

Cancer Gene Ther. 2004 Mar;11(3):227-36.

PMID:
14726960
5.

In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.

Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E.

Clin Cancer Res. 2006 Mar 15;12(6):1921-7.

6.

Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.

Lopes L, Fletcher K, Ikeda Y, Collins M.

Cancer Immunol Immunother. 2006 Aug;55(8):1011-6. Epub 2005 Nov 26.

PMID:
16311731
7.

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2005 Feb 1;174(3):1751-9.

8.

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.

Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.

Clin Cancer Res. 2004 Oct 15;10(20):6946-55.

9.

Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.

Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK.

J Immunol. 2004 Feb 1;172(3):1582-7.

10.

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.

Maraskovsky E, Sjölander S, Drane DP, Schnurr M, Le TT, Mateo L, Luft T, Masterman KA, Tai TY, Chen Q, Green S, Sjölander A, Pearse MJ, Lemonnier FA, Chen W, Cebon J, Suhrbier A.

Clin Cancer Res. 2004 Apr 15;10(8):2879-90.

11.

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.

Blood. 2005 Mar 15;105(6):2465-72. Epub 2004 Nov 16.

13.

Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population.

Ohkuri T, Sato M, Abe H, Tsuji K, Yamagishi Y, Ikeda H, Matsubara N, Kitamura H, Nishimura T.

Cancer Sci. 2007 Jul;98(7):1092-8. Epub 2007 May 4.

14.

[Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].

Qiao H, Qian XP, Zhang HG, Tian C, Chen WF.

Beijing Da Xue Xue Bao. 2005 Dec 18;37(6):565-8. Chinese.

15.

Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells.

Hu Y, Cheng SC, Chan KT, Ke Y, Xue B, Sin FW, Zeng C, Xie Y.

Biochem Biophys Res Commun. 2010 Feb 12;392(3):329-34. doi: 10.1016/j.bbrc.2010.01.018. Epub 2010 Jan 11.

PMID:
20067767
16.

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

Qian J, Wang S, Yang J, Xie J, Lin P, Freeman ME 3rd, Yi Q.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8808-15.

17.

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S.

J Immunol. 2009 Feb 1;182(3):1253-9. Erratum in: J Immunol. 2009 Apr 15;182(8):5152.

18.

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.

Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, Fox BA, Renner C, Petrausch U.

Gene Ther. 2013 Apr;20(4):386-95. doi: 10.1038/gt.2012.48. Epub 2012 Jun 28.

PMID:
22739387
19.

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.

Eur J Immunol. 2004 Oct;34(10):2919-29.

20.

NY-ESO-1 immunotherapy for multiple myeloma.

Szmania S, Tricot G, van Rhee F.

Leuk Lymphoma. 2006 Oct;47(10):2037-48. Review.

PMID:
17071474

Supplemental Content

Support Center